Rhumbline Advisers Neu Base Therapeutics, Inc. Transaction History

Rhumbline Advisers

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	SELL	$4.63 - $7.34 $74,890 - $118,724	-16,175 Closed	0 $0
Q1 2021 May 06, 2021	SELL	$6.92 - $12.36 $2,906 - $5,191	-420 Reduced 2.53%	16,175 $120,000
Q4 2020 Feb 10, 2021	BUY	$6.92 - $9.25 $8,511 - $11,377	1,230 Added 8.01%	16,595 $116,000
Q3 2020 Nov 12, 2020	SELL	$7.25 - $9.71 $3,110 - $4,165	-429 Reduced 2.72%	15,365 $117,000
Q2 2020 Aug 13, 2020	BUY	$6.69 - $11.51 $105,661 - $181,788	15,794 New	15,794 $139,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.